Cargando…
Combined vitamin D, ibuprofen and glutamic acid decarboxylase-alum treatment in recent onset Type I diabetes: lessons from the DIABGAD randomized pilot trial
AIM: Double-blind placebo-controlled intervention using glutamic acid decarboxylase (GAD)-alum, vitamin D and Ibuprofen in recent onset Type I diabetes (T1D). METHODS: 64 patients (T1D since <4 months, age 10–17.99, fasting sC-peptide ≥0.12 nmol/l, GADA-positive) were randomized into Day(D) 1–90...
Autores principales: | Ludvigsson, Johnny, Routray, Indusmita, Elluru, Sriramulu, Leanderson, Per, Larsson, Helena E, Rathsman, Björn, Hanås, Ragnar, Carlsson, Annelie, Ek, Torben, Samuelsson, Ulf, Torbjörnsdotter, Torun, Åman, Jan, Örtqvist, Eva, Badwal, Karun, Beam, Craig, Casas, Rosaura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Science Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7421935/ https://www.ncbi.nlm.nih.gov/pubmed/32802401 http://dx.doi.org/10.2144/fsoa-2020-0078 |
Ejemplares similares
-
Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes
por: Tavira, Beatriz, et al.
Publicado: (2018) -
Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes
por: Hannelius, Ulf, et al.
Publicado: (2020) -
Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD(65)-induced immune response
por: Tavira, Beatriz, et al.
Publicado: (2017) -
Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2
por: Nowak, Christoph, et al.
Publicado: (2022) -
Cellular and Humoral Immune Responses in Type 1 Diabetic Patients Participating in a Phase III GAD-alum Intervention Trial
por: Axelsson, Stina, et al.
Publicado: (2013)